Quellenverzeichnis Reizdarm, SIBO & IMO

Zu meinem Onlinekurs "SIBO verstehen & behandeln"

Verzeichnis wichtiger Studien, Literatur und anderer Quellen, auf die ich bei meinen Forschungen und Recherchen zum Thema Reizdarm, SIBO und IMO zurückgegriffen habe

  • A AJ, Suresh A: Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives. In: J Oral Biol Craniofac Res. 2023 May-Jun;13(3):398-402.
  • Achufusi TGO, Sharma A, Zamora EA, Manocha D. Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. 2020 Jun 27;12(6):e8860.
  • Acosta A, Camilleri M: Prokinetics in gastroparesis. In: Gastroenterol Clin North Am. 2015 Mar;44(1):97-111.
  • Adike A, DiBaise JK: Small Intestinal Bacterial Overgrowth: Nutritional Implications, Diagnosis, and Management. Gastroenterol Clin North Am. 2018 Mar;47(1):193-208.
  • Ärztezeitung: Stress nach Trauma erhöht Reizdarmrisiko. Veröffentlicht am 11.12.2014. Abrufbar unter:  https://www.aerztezeitung.de/Medizin/Stress-nach-Trauma-erhoeht-Reizdarmrisiko-239832.html. Abgerufen am 03.03.2024.
  • Aguilar A, Benslaiman B, Serra J: Effect of Iberogast® (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome: A randomized, double-blind, placebo control clinical trial. In: Neurogastroenterol Motil. 2024 Feb 15:e14765.
  • Ahuja A, Ahuja NK: Popular Remedies for Esophageal Symptoms: a Critical Appraisal. In: Curr Gastroenterol Rep. 2019 Jul 10;21(8):39.
  • Allescher HD, et al.: Multi-target Treatment for Irritable Bowel Syndrome with STW 5: Pharmacological Modes of Action. J Gastrointestin Liver Dis. 2020 Jun 3;29(2):227-233.               
  • Allescher HD, Wagner H: STW 5/Iberogast®: Multi-Target-Wirkung bei funktioneller Dyspepsie und Reizdarmsyndrom. In: Wien Med Wochenschr. 2007;157(13-14):301-307.
  • Alqudah M, et al.: Progesterone Inhibitory Role on Gastrointestinal Motility. In: Physiol Res. 2022 Apr; 71(2): 193-198. Published online 2022 Mar 28.
  • Álvarez-Martínez FJ, et al.: Antibacterial plant compounds, extracts and essential oils: An updated review on their effects and putative mechanisms of action. In: Phytomedicine. 2021 Sep:90:153626.
  • Ammon HP, Kelber O, Okpanyi SN: Spasmolytic and tonic effect of Iberogast® (STW 5) in intestinal smooth muscle. In: Phytomedicine. 2006;13 Suppl 5:67-74.
  • Arasu A, et al.: Antimicrobial Efficacy of Allium cepa and Zingiber officinale Against the Milk-Borne Pathogen Listeria monocytogenes. In: J Microbiol. 2023 Nov;61(11):993-1011.
  • Arip M, et al.: Review on Plant-Based Management in Combating Antimicrobial Resistance – Mechanistic Perspective. In: Front Pharmacol. 2022; 13:879495.
  • Assiry AA, et al.: The antioxidant activity, preliminary phytochemical screening of Zingiber zerumbet and antimicrobial efficacy against selective endodontic bacteria. In: Food Sci Nutr. 2023 Jun 1;11(8):4853-4860.
  • Attar A, et al.: Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. In: Gastroenterology. 1999 Oct;117(4):794-797.
  • Aulenkamp J, et al.: Vom Bauchgefühl zum viszeralen Schmerz. In: Schmerz. 2022; 36(3):182–188.
  • Axt-Gadermann M.: Gesund mit Darm. Südwest 2020.
  • Báez G, et al.: Non-Chinese herbal medicines for functional dyspepsia. Cochrane Database Syst Rev. 2023 Jun 15;6(6):CD013323.
  • Barahona G, et al.: Improving the Diagnosis of Small Intestinal Bacterial Overgrowth Using an At-Home Handheld App Connected Breath Analysis Device (AIRE). Pre-print. Veröffentlicht am 21.04.2022. Abrufbar unter: https://www.medrxiv.org/content/10.1101/2022.04.21.22274143v1.full. Abgerufen am 04.04.2024.
  • Barkin JA, et al.: Preferential usage of rifaximin for the treatment of hydrogen-positive small intestinal bacterial overgrowth. In: Rev Gastroenterol Peru. 2019 Apr-Jun;39(2):111-115.
  • Barnert J, Wienbeck M: Schwerpunkt: Motilitätsstörungen im Verdauungstrakt. In: Dtsch Arztebl 1996; 93(4): A-176 / B-146 / C-142.
  • Bartolini M, et al.: Regulation of Biofilm Aging and Dispersal in Bacillus subtilis by the Alternative Sigma Factor SigB. In: J Bacteriol. 2018 Dec 20;201(2):e00473-18.
  • Bastiani RDE, et al.: Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care. In: Minerva Gastroenterol (Torino). 2023 Dec;69(4):523-528.
  • Baumgartner M, et al.: Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative Colitis. In: Gastroenterology. 2021 Oct;161(4):1245-1256.
  • Benson TM, Wald A: Small Intestinal Bacterial Overgrowth Syndrome: A Guide for the Appropriate Use of Breath Testing. In: Dig Dis Sci. 2021 Feb;66(2):338-347.
  • Bernardeau M, et al.: Importance of the gastrointestinal life cycle of Bacillus for probiotic functionality. In: J Food Sci Technol. 2017 Jul;54(8):2570-2584.
  • Bested AC, Logan AC, Selhub EM: Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part I – autointoxication revisited. In: Gut Pathog. 2013 Mar 18;5(1):5.
  • Beutling DM: Biogene Amine in der Ernährung. Springer Verlag 1996.
  • Bhalla V, et al.: Nattokinase For Biofilm Disruption. In: Res Med Dent Sci, 2022; 10(S1):124-130.
  • Bierer DW: Bismuth subsalicylate: history, chemistry, and safety. In: Rev Infect Dis. 1990 Jan-Feb:12 Suppl 1:3-8.
  • Biovis: https://www.biovis.eu/de/
  • Birg A, Hu S, Lin HC: Reevaluating our understanding of lactulose breath tests by incorporating hydrogen sulfide measurements. In: JGH Open. 2019 Feb 22;3(3):228-233.
  • Birg A, Hu S, Lin HC: Mo1577 – Breath Hydrogen Sulfide Does not Correlate with Constipation. In: AGA Abstracts. 2018 May; 154(6):S-758.
  • Black CJ, Staudacher HM, Ford AC: Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. In: Gut. 2022 Jun;71(6):1117-1126.
  • Bohm M, Siwiec RM, Wo J: Diagnosis and management of small intestinal bacterial overgrowth. In: Nutr Clin Pract. 2013 Jun;28(3):289-99.
  • Bonaz B: Unmet needs of drugs for irritable bowel syndrome and inflammatory bowel diseases: interest of vagus nerve stimulation and hypnosis. In: Inflammopharmacology. Veröffentlicht am 2024 Mar 21. Epub ahead of print. Abrufbar unter: https://pubmed.ncbi.nlm.nih.gov/38512653/.
  • Bonaz B, Sinniger V: Targeting the Vagus Nerve to Treat Inflammatory Bowel Disease? In:  J Crohns Colitis. 2023 Dec 30;17(12):1893-1894.
  • Bora G, et al.: Impact of auricular percutaneous electrical nerve field stimulation on gut microbiome in adolescents with irritable bowel syndrome: A pilot study. In: J Dig Dis. 2023 May;24(5):348-358.
  • Brass L: 8 Herbal Antibiotics and Supplements to Treat SIBO. Veröffentlicht am 08.10.2021. Abrufbar unter: https://drlaurabrass.com/blogs/news/8-herbal-antibiotics-and-supplements-to-treat-sibo. Abgerufen am 02.04.2024.
  • Brody R: SIBO-HS: Hydrogen Sulfide (H2S). Abrufbar unter: https://brodynd.com/sibo-hs-hydrogen-sulfide-h2s/. Abgerufen am 26.03.2024.
  • Brown K, Scott-Hoy B, Jennings LW: Response of irritable bowel syndrome with constipation patients administered a combined quebracho/conker tree/M. balsamea Willd extract. In: World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):463-468.
  • Bruck R, et al.: Allicin, the active component of garlic, prevents immune-mediated, concanavalin A-induced hepatic injury in mice. In: Liver Int. 2005 Jun;25(3):613-621.
  • Buhner SH: Herbal Antibiotics. Natural alternatives for treating drug-resistant bacteria. Storey Publishing. 2. Auflage 2012.
  • Buhner SH: Herbal Antivirals. Natural remedies for emerging & resistant viral infections. Storey Publishing. 2. Auflage 2013.
  • Bundesamt für Arzneimittel und Medizinprodukte (BfArM): Rote-Hand-Brief zu neuen Kontraindikationen von Saccharomyces boulardii (Saccharomyces cerevisiae HANSEN CBS 5926) bei schwerkranken oder immunsupprimierten Patienten. Veröffentlicht am 22.01.2018. Abrufbar unter: https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-saccharomyces_boulardii.html. Abgerufen am 30.03.2024.
  • Cangemi DJ, Lacy BE, Wise J. Diagnosing small intestinal bacterial overgrowth: a comparison of lactulose breath tests to small bowel aspirates. In: Dig Dis Sci. 2021;66(6):2042–2050.
  • Cangemi DJ, Lacy BE: A Practical Approach to the Diagnosis and Treatment of Abdominal Bloating and Distension. In: Gastroenterol Hepatol (N Y). 2022 Feb; 18(2):75–84.
  • Chander Roland B, et al.: A Prospective Evaluation of Ileocecal Valve Dysfunction and Intestinal Motility Derangements in Small Intestinal Bacterial Overgrowth. In: Dig Dis Sci. 2017 Dec;62(12):3525-3535.
  • Chang C: Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. In: Clin Exp Gastroenterol. 2018 Sep 24:11:335-345.
  • Chang CW, et al.: Bacillus coagulans (PROBACI) in treating constipation-dominant functional bowel disorders. In: Medicine (Baltimore). 2020 May;99(19):e20098.
  • Chedid V, et al.: Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. In: Glob Adv Health Med. 2014 May;3(3):16-24.
  • Cheng Y, et al.: Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. In: Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2316-2323.
  • Cherry RN, et al.: Herbal Approaches to Pediatric Functional Abdominal Pain. Children (Basel). 2022 Aug 22;9(8):1266.
  • Chiotakakou-Faliakou E, et al.: Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. In: Gut. 1998;42(4):517–521.
  • Cho YK, Lee J, Paik CN: Prevalence, risk factors, and treatment of small intestinal bacterial overgrowth in children. In: Clin Exp Pediatr. 2023 Sep;66(9):377-383.
  • Chonchubhair HMN, et al.: The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). In: Pancreatology. 2018 Jun;18(4):379-385.
  • Crew B: Here’s How Many Cells in Your Body Aren’t Actually Human. Veröffentlicht am 11.04.2018. Abrufbar unter: https://www.sciencealert.com/how-many-bacteria-cells-outnumber-human-cells-microbiome-science. Abgerufen am 16.04.2024.
  • Crichton M, et al.: Effect of Ginger Root Powder on Gastrointestinal Bacteria Composition, Gastrointestinal Symptoms, Mental Health, Fatigue, and Quality of Life: A Double-Blind Placebo-Controlled Trial. In: J Nutr. 2023 Nov;153(11):3193-3206.
  • Chromatest: www.chromatest.de
  • Chuah KH, et al.: Impact of small intestinal bacterial overgrowth on symptoms and quality of life in irritable bowel syndrome. In: J Dig Dis. 2023 Mar;24(3):194-202.
  • Dănău A, et al.: Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson’s Disease. In: Int J Mol Sci. 2021 Oct 28;22(21):11663.
  • Dass NB, et al.: The relationship between the effects of short-chain fatty acids on intestinal motility in vitro and GPR43 receptor activation. In: Neurogastroenterol Motil. 2007 Jan;19(1):66-74.
  • De Meirleir K: PUBLISHED NEWS: Dr. Kenny De Meirleir Announces He has Revealed the True Nature of ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome). Veröffentlicht am 28.05.2009. http://www.91outcomes.com/2009/05/published-news-dr-kenny-de-meirleir.html. Abgerufen am 29.03.2024.
  • De Santis A: S. Boulardii Probiotics For SIBO – Do They Help? Veröffentlicht am 24.03.2024. Abrufbar unter: https://andytherd.com/2023/03/24/s-boulardii-probiotics-for-sibo-do-they-help/. Abgerufen am 30.03.2024.
  • Deepa B, Anuradha CV: Antioxidant potential of Coriandrum sativum L. seed extract. In: Indian J Exp Biol. 2011 Jan;49(1):30-38.
  • Deloose E, et al.: The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012 Mar 27;9(5):271-285.
  • Deutsche Apothekerzeitung: Die unterschätzte Welt der Archaea. Veröffentlicht am 26.04.2023. Abrufbar unter: https://www.deutsche-apotheker-zeitung.de/news/artikel/2023/04/26/die-unterschaetzte-welt-der-archaea. Abgerufen am 27.03.2024.
  • Deutsche Gesellschaft für Ernährung e.V. https://www.dge.de/
  • Dharan M, Wozny D: Helicobacter pylori infection and small intestinal bacterial overgrowth–more than what meets the eye. In: World J Clin Cases. 2022 Jul 26; 10(21):7209–7214.
  • DiBaise JK: Nutritional consequences of small intestinal bacterial overgrowth. In: Practical Gastroenterology, 2008 Dec;32(12):15-28.
  • Dicks LMT, et al.: Clostridium difficile, the Difficult „Kloster“ Fuelled by Antibiotics. In: Curr Microbiol. 2019 Jun;76(6):774-782.
  • Dinleyici EC, et al.: Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. In: Parasitol Res. 2011 Mar;108(3):541–545.
  • Dordevic D, et al.: Sulfur content in foods and beverages and its role in human and animal metabolism: A scoping review of recent studies. In: Heliyon. 2023 Apr 13;9(4):e15452.
  • Dudzinska E, et al.: The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome—Plant Metabolites in IBS Treatment. In: Pharmaceuticals 2023, 16(10):1405.
  • van Tilburg MA, et al.: Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. In: Complement Ther Med. 2014 Feb;22(1):17-20.
  • Efremova I, et al.: Efficacy and Safety of a Probiotic Containing Saccharomyces boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis: Randomized, Placebo-Controlled Study. In: J Clin Med. 2024 Feb 5;13(3):919.
  • Ekert D et al.: Migrierender motorischer Komplex. Veröffentlicht am 08.2003.22. Abrufbar unter:  https://flexikon.doccheck.com/de/Migrierender_motorischer_Komplex. Abgerufen am 02.04.2024.
  • El-Omar EM, et al.: Helicobacter pylori infection and chronic gastric acid hyposecretion. In: Gastroenterology. 1997 Jul;113(1):15-24.
  • Enders G: Darm mit Charme. Alles über ein unterschätztes Organ. Ullstein, 5. Auflage 2017.
  • Fan C, et al.: Development of an antimicrobial resin–a pilot study. In: Dent Mater. 2011 Apr;27(4):322-328.
  • Farzaei MH, et al.: The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. In: J Neurogastroenterol Motil. 2016 Oct; 22(4):558–574.
  • Feng X, Li XQ: The prevalence of small intestinal bacterial overgrowth in diabetes mellitus: a systematic review and meta-analysis. In: Aging (Albany NY). 2022 Jan 27;14(2):975-988.
  • Fernández LMB, Man F, Lasa JS: Impact of Saccharomyces boulardii CNCM I-745 on Bacterial Overgrowth and Composition of Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Patients: Results of a Randomized Pilot Study. In: Dig Dis. 2023;41(5):798-809.
  • Foley A, et al.: Management strategies for abdominal bloating and distension. In: Gastroenterol Hepatol (N Y). 2014;10(9):561-571.
  • Ford AC, et al.: Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. In: Aliment Pharmacol Ther. 2018 Nov;48(10):1044-1060.
  • Furnari M, et al.: Sa2058 Efficacy of Partially Hydrolyzed Guar Gum in Reducing Methane Excretion and Clinical Manifestation of Subjects Suffering From Irritable Bowel Syndrome. In: Gastroenterology. 142(5):S-391.
  • Furnari M, et al.: Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. In: Aliment Pharmacol Ther. 2010 Oct;32(8):1000-1006.
  • Gabrielli M, et al.: Diagnosis of small intestinal bacterial overgrowth in the clinical practice. In: Eur Rev Med Pharmacol Sci. 2013:17 Suppl 2:30-35.
  • Gabrielli M, et al.: Bacillus clausii as a treatmeMore than half your body is not humannt of small intestinal bacterial overgrowth. In: Am J Gastroenterol. 2009 May;104(5):1327-1328.
  • Gallagher J: More than half your body is not human. Veröffentlicht am 10.04.2018. Abrufbar unter: https://www.bbc.com/news/health-43674270. Abgerufen am 16.04.2024.
  • GanzImmun: https://www.ganzimmun.de/
  • GanzImmun Diagnostics: Fachinformation 0045 Nitrostress. Abrufbar unter: https://www.ganzimmun.de/service/download-center. Abgerufen am 15.07.2023.
  • GanzImmun Diagnostics: Fachinformation 0081 Oxidativer Stress. Abrufbar unter: https://www.ganzimmun.de/service/download-center. Abgerufen am 15.07.2023.
  • GanzImmun Diagnostics: Fachinformation 0146 Gallensäureverlust-Syndrom. Diagnostik und Therapie einer unterschätzten Erkrankung. Abrufbar unter: https://www.ganzimmun.de/service/download-center. Abgerufen am 15.07.2023.
  • García-Collinot G, et al.: Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. In: Dig Dis Sci. 2020 Apr;65(4):1134–1143.
  • Gatta L, Scarpignato C: Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. In: Aliment Pharmacol Ther. 2017 Mar;45(5):604-616.
  • Gebrayel P, et al.: Microbiota medicine: towards clinical revolution. In: J Transl Med. 2022 Mar 7;20(1):111.
  • Gesund & aktiv: http://www.gesund-aktiv.com
  • Ghayur MN, Khan AH, Gilani AH: Ginger facilitates cholinergic activity possibly due to blockade of muscarinic autoreceptors in rat stomach fundus. In: Pak J Pharm Sci. 2007 Jul;20(3):231-235.
  • Gianella RA, Rout WR, Toskes PP: Jejunal brush border injury and impaired sugar and amino acid uptake in the blind loop syndrome. In: Gastroenterology. 1974 Nov;67(5):965-974.
  • Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. In: J Nutr. 1995 Jun;125(6):1401-1412.
  • Gibson GR, et al.: Alternative pathways for hydrogen disposal during fermentation in the human colon. Gut. 1990;31(6):679–683.
  • Gibson PR, Shepherd SJ: Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. In: J Gastroenterol Hepatol. 2010 Feb;25(2):252-258.
  • Givskov M: Beyond nutrition: health-promoting foods by quorum-sensing inhibition. In: Future Microbiol. 2012 Sep;7(9):1025-1028.
  • Ghoshal UC, Shukla R, Ghoshal U: Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. In: Gut Liver. 2017 Mar 15;11(2):196-208.
  • Glowatzki F: Die Rolle von Laktat produzierenden Milchsäurebakterien bei Kindern mit Kurzdarmsyndrom und D-Laktat Azidose assoziierter Encephalopathie. Dissertation 2015. Abrufbar unter: https://docplayer.org/25433323-Die-rolle-von-laktat-produzierenden-milchsaeurebakterien-bei-kindern-mit-kurzdarmsyndrom-und-d-laktat-azidose-assoziierter-encephalopathie.html. Abgerufen am 05.02.2014.
  • Goebel A, et al.: Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. In: Rheumatology (Oxford). 2008 Aug;47(8):1223-1227.
  • Goodoory VC, Ford AC: Antibiotics and Probiotics for Irritable Bowel Syndrome. In: Drugs. 2023 Jun;83(8):687-699.
  • Goto S, Billmire DF, Grosfeld JL: Hypothyroidism impairs colonic motility and function. An experimental study in the rat. Eur J Pediatr Surg. 1992 Feb;2(1):16-21.
  • Grace E, et al.: Review article: small intestinal bacterial overgrowth—prevalence, clinical features, current and developing diagnostic tests, and treatment. In: Aliment Pharmacol Ther. 2013;38(7):674-688.
  • Gröber U: Mikronährstoffe. Metabolic Tuning – Prävention – Therapie. Wissenschaftliche Verlagsgesellschaft Stuttgart. 3., völlig überarbeitete und erweiterte Auflage 2011.
  • Gudan A, et al.: Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023? In: Nutrients. 2023 Mar 8;15(6):1323.
  • Guo Y, et al.: Repeated administration of berberine inhibits cytochromes P450 in humans. In: Eur J Clin Pharmacol. 2012 Feb;68(2):213-217.
  • Gupta AK, Maity C: Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. In: Medicine (Baltimore). 2021 Jan 22;100(3):e23641.
  • Hagmeyer R: Biofilm Disruptors – How You Can Eradicate SIBO. Veröffentlicht am 09.07.2018. Abrufbar unter: https://www.drhagmeyer.com/biofilm-disruptors/. Abgerufen am 29.03.2024.
  • Hamzah H, et al.: The biofilm inhibition and eradication activity of curcumin againts polymicrobial biofilm. In: BIO Web Conf. Volume 28, 2020. The 3rd International Conference on Bioinformatics, Biotechnology, and Biomedical Engineering (BioMIC 2020). Abrufbar unter: https://doi.org/10.1051/bioconf/20202804001.
  • Hanson BT, et al.: Sulfoquinovose is a select nutrient of prominent bacteria and a source of hydrogen sulfide in the human gut. In: ISME J. 2021 Sep;15(9):2779-2791.
  • Harris JC, et al.: Antimicrobial properties of Allium sativum (garlic). In: Appl Microbiol Biotechnol. 2001 Oct;57(3):282-6.
  • Haworth J, et al.: Small intestinal bacterial overgrowth is associated with laryngopharyngeal reflux symptom severity and impaired esophageal mucosal integrity. In: Gastrointestinal Tract 1. 2023 Nov;1(10). Abrufbar unter: https://www.researchgate.net/publication/375465441_Small_intestinal_bacterial_overgrowth_is_associated_with_laryngopharyngeal_reflux_symptom_severity_and_impaired_esophageal_mucosal_integrity. Abgerufen am 07.04.2024.
  • Hesampour F, Bernstein CN, Ghia JE: Brain-Gut Axis: Invasive and Noninvasive Vagus Nerve Stimulation, Limitations, and Potential Therapeutic Approaches. In: Inflamm Bowel Dis. 2024 Mar 1;30(3):482-495.
  • Heyland K, et al.: No advantage for antibiotic treatment over placebo in Blastocystis hominis-positive children with recurrent abdominal pain. In: J Pediatr Gastroenterol Nutr. 2012 May;54(5):677–679.
  • Hoegenauer C, et al.: Methanogenic archaea in the human gastrointestinal tract. In: Nat Rev Gastroenterol Hepatol. 2022 Dec;19(12):805-813.
  • Hokanson KC, et al.: Sex shapes gut-microbiota-brain communication and disease. In: Trends Microbiol. 2024 Feb;32(2):151-161.
  • Holtmann G, Adam B, Vinson B: Evidenz-basierte Medizin und Phytotherapie bei funktioneller Dyspepsie und Reizdarmsyndrom: Eine systematische Analyse der verfügbaren Evidenz zum Präparat Iberogast®. In: Wien Med Wochenschr. 2004 Nov;154(21-22):528-534.
  • Holtmann G, Kriebel R, Singer MV: Mental stress and gastric acid secretion. Do personality traits influence the response? In: Dig Dis Sci. 1990 Aug;35(8):998-1007.
  • Hu M-L, et al.: Effect of ginger on gastric motility and symptoms of functional dyspepsia. In: World J Gastroenterol. 2011 Jan 7;17(1):105-110.
  • Huang CW, et al.: Hydrogen sulfide and its roles in Saccharomyces cerevisiae in a winemaking context. In: FEMS Yeast Res. 2017 Sep 1;17(6).
  • IMD Labor Berlin: Probiotikaauswahl bei Histaminbelastung. Abrufbar unter: https://www.imd-berlin.de/fachinformationen/diagnostikinformationen/300-399/351-probiotikaauswahl-bei-histaminbelastung. Abgerufen am 09.04.2024.
  • Imhann F, et al.: Proton pump inhibitors affect the gut microbiome. Gut. 2016 May;65(5):740-748.
  • Jackson MA, et al.: Proton pump inhibitors alter the composition of the gut microbiota. In: Gut. 2016 May;65(5):749-756.
  • Jacobi N: SIBO-Bi-Phasic Diet. The SIBO Doctor. 2023 Edition. Abrufbar unter: https://www.thesibodoctor.com/sibo-bi-phasic-diet-e-book/. Abgerufen am 02.04.2024.
  • Jain NK, Patel VP, Pitchumoni CS: Efficacy of activated charcoal in reducing intestinal gas: a double-blind clinical trial. In: Am J Gastroenterol. 1986 Jul;81(7):532-535.
  • Jakubczyk D, Leszczyńska K, Górska S: The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)-A Critical Review. In: Nutrients. 2020;12:1973.
  • Jamal M, et al.: Bacterial biofilm and associated infections. In: J Chin Med Assoc. 2018 Jan;81(1):7-11.
  • Jee SR, et al.: ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. In: World J Gastroenterol. 2010 Aug 7; 16(29):3680-3686.
  • Jiang W, et al.: The Role of Short Chain Fatty Acids in Irritable Bowel Syndrome. In: J Neurogastroenterol Motil. 2022 Oct 30; 28(4):540-548.
  • Jonas A, Krishnan C, Forstner G: Pathogenesis of mucosal injury in the blind loop syndrome: Release of disaccharidases from brush border membranes by extracts of bacteria obtained from intestinal blind loops in rats. In: Gastroenterology. 1978 Nov; 75(5):791-795.
  • Jones M: Herbal Antibiotics. What big pharma doesn’t want you to know. 2016.
  • Kalantar-Zadeh K, et al.: Intestinal gases: influence on gut disorders and the role of dietary manipulations. In: Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):733-747.
  • Kalman DS, et al.: A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. In: BMC Gastroenterol. 2009 Nov 18;9:85.
  • Karunasagar D, et al.: Removal and preconcentration of inorganic and methyl mercury from aqueous media using a sorbent prepared from the plant Coriandrum sativum. In: Journal of Hazardous Materials. 2005 Feb 14; 118(1–3):133-139.
  • Karuppiah S, Pomianowski K: Rifaximin (Xifaxan) for Irritable Bowel Syndrome. In: Am Fam Physician. 2017 Feb 15;95(4):258-259.
  • Kaufman SS, et al.: Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. In: J Pediatr. 1997 Sep;131(3):356-361.
  • Keller J, et al.: Update S3-Leitlinie Intestinale Motilitätsstörungen: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). In: Z Gastroenterol. 2022; 60:192-218.
  • Khalighi AR, et al.: Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)–a pilot study. In: Indian J Med Res. 2014 Nov;140(5):604-608.
  • Khameneh B, et al.: Review on plant antimicrobials: a mechanistic viewpoint. In: Antimicrob Resist Infect Control. 2019 Jul 16:8:118.
  • Khan Z, et al.: Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. In: Cureus. 2023 Sep 6;15(9):e44807.
  • Kim JH et al.: Association between interstitial cells of Cajal and anti-vinculin antibody in human stomach. In: Korean J Physiol Pharmacol. 2020 Mar; 24(2):185-191.
  • Kim YS, et al.: Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication. Front Psychiatry. 2020 Jul 10;11:601.
  • Kitaghenda FK, et al.: The Prevalence of Small Intestinal Bacterial Overgrowth After Roux-en-Y Gastric Bypass (RYGB): a Systematic Review and Meta-analysis. In: Obes Surg. 2024 Jan;34(1):250-257.
  • Konrad P, et al.: Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth and Helicobacter pylori infection. In: Prz Gastroenterol. 2018;13(3):213-217.
  • Krogsgaard LR, et al.: Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. In: Clin Transl Gastroenterol. 2018 Jun 19;9(6):161.
  • Khoshini R, et al.: A systematic review of diagnostic tests for small intestinal bacterial overgrowth. In: Dig Dis Sci. 2008;53:1443.
  • Krueger D, et al.: The multi-herbal drug STW 5 (Iberogast®) has prosecretory action in the human intestine. In: Neurogastroenterol Motil. 2009 Nov;21(11):1203-e110.
  • Laborgemeinschaft für ganzheitliche Medizin: https://lgm-hh.de/
  • Lacy BE, et al.: ACG Clinical Guideline: management of irritable bowel syndrome. In: Am J Gastroenterol. 2021;116(1):17-44.
  • Lacy BE, et al.: Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points. In: Clin Ther. 2023 Mar;45(3):198-209.
  • Lakhan SE, Kirchgessner A: Gut inflammation in chronic fatigue syndrome. In: Nutr Metab (Lond). 2010 Oct 12:7:79.
  • Larson JM, et al.: Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. In: J Neurogastroenterol Motil. 2010 Oct;16(4):407-413.
  • Lauritano EC, et al.: Small intestinal bacterial overgrowth and intestinal permeability. In: Scand J Gastroenterol. 2010 Sep;45(9):1131-1132.
  • Lauritano EC, et al.: Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. In: Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):111-116.
  • Lauritano EC, et al.: Small intestinal bacterial overgrowth recurrence after antibiotic therapy. In: Am J Gastroenterol. 2008 Aug;103(8):2031-2035.
  • Lauritano EC, et al.: Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab. 2007 Nov;92(11):4180-4184.
  • Lauritano EC, et al.: Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. In: Aliment Pharmacol Ther. 2005 Jul 1;22(1):31-35.
  • Layer P, et al.: Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Juni 2021 AWMF-Registriernummer: 021/016. Abrufbar unter:
    https://www.dgvs.de/leitlinien/unterer-gi-trakt/reizdarmsyndrom/. Abgerufen am 30.03.2024.
  • Lazzini S, et al.: The effect of ginger (Zingiber officinalis) and artichoke (Cynara cardunculus) extract supplementation on gastric motility: a pilot randomized study in healthy volunteers. In: Eur Rev Med Pharmacol Sci. 2016;20(1):146-149.
  • Lee H-R, Pimentel, M: Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. In: Curr Gastroenterol Rep. 2006 Aug;8(4):305-311.
  • Leitzmann C, et al.: Ernährung in Prävention und Therapie. Ein Lehrbuch. Hippokrates, 3. vollständig überarbeitete und erweiterte Auflage 2009.
  • Lemle MD: Hypothesis: chronic fatigue syndrome is caused by dysregulation of hydrogen sulfide metabolism. In Med Hypotheses. 2009 Jan;72(1):108-109.
  • Leventogiannis K, et al.: Correction to: Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. In: Probiotics Antimicrob Proteins. 2019 Jun;11(2):627-634.
  • Levitt MD, et al.: Physiology of sulfide in the rat colon: use of bismuth to assess colonic sulfide production. In: J Appl Physiol (1985). 2002 Apr;92(4):1655-1660.
  • Li J, et al.: Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. In: Medicine (Baltimore). 2016 Jan;95(4):e2534.
  • Li N, et al.: Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. In: E ur J Pharm Sci. 2010 Apr 16;40(1):1-8.
  • Lombardo L, et al.: Increased incidence of small intestinal berial overgrowth during proton pump inhibitor therapy. In: Clin Gastroenterol Hepatol. 2010 Jun;8(6):504-508.
  • Longo S, Rizza S, Federici M: Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes. In: Acta Diabetol. 2023 Aug;60(8):1007-1017.
  • Losurdo G, et al.: The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. Int J Mol Sci. 2020 May 16;21(10):3531
  • Luciardi MC, et al.: Grapefruit essential oils inhibit quorum sensing of Pseudomonas aeruginosa. In: Food Science and Technology International. Volume 26 (3). Veröffentlicht am 05.11.2019. Abrufbar unter: https://doi.org/10.1177/1082013219883465. Abgerufen am 02.04.2024.
  • Lüddemann, H: Magensäure – zu viel oder zu wenig? (Interview mit M. Murray von Enzymedica). Veröffentlicht am 22.10.2020. Abrufbar unter: https://www.supplementa.com/magazin/magensaeure-zu-viel-oder-zu-wenig-interview-mit-m-murray-von-enzymedica/. Abgerufen am 12.05.2024.
  • Ma ZF, Lee YY: Small intestine anatomy and physiology. In: Clinical and Basic Neurogastroenterology and Motility. Science Direct. 2020:101-111.
  • Madisch A, et al.: Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. In: Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-279.
  • Maeda Y, Murakami T: Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth. In: Antibiotics (Basel). 2023 Jan 28;12(2):263.
  • Mafra D, et al.: Archaea from the gut microbiota of humans: Could be linked to chronic diseases? In: Anaerobe. 2022 Oct:77:102629.
  • Majeed M, et al.: The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. In: Medicine (Baltimore). 2023 Mar 3;102(9):e33109.
  • Malfertheiner P: STW 5 (Iberogast®) Therapy in Gastrointestinal Functional Disorders. In: Dig Dis. 2017;35 Suppl 1:25-29.
  • Manabe N, et al.: Emerging pharmacologic therapies for irritable bowel syndrome. In: Curr Gastroenterol Rep. 2010 Oct;12(5):408-416.
  • Mancilla, C, et al.: Small intestine bacterial overgrowth in patients with chronic pancreatitis. In: Rev Med Chil. 2008 Aug;136(8):976-980.
  • Mann N, Cheung E: Activated Charcoal Reduces Lactulose-Induced Breath Hydrogen in Patients with Excessive Gas and in Controls. Veröffentlicht im Dezember 2003. Abrufbar unter: https://www.researchgate.net/publication/312536337_Activated_Charcoal_Reduces_Lactulose-Induced_Breath_Hydrogen_in_Patients_with_Excessive_Gas_and_in_Controls
    Abgerufen am 26.03.2024.
  • Mansfield T: Probiotics for SIBO – Helpful or Harmful? Veröffentlicht am 14.12.2020. Abrufbar unter: https://www.byronherbalist.com.au/prebiotics-probiotics/probiotics-for-sibo-helpful-or-harmful/. Abgerufen am 30.03.2024.
  • Mansfield T: SIBO: The Complete Guide To Small Intestinal Bacterial Overgrowth. Veröffentlicht am 12.10.2019. Abrufbar unter: https://www.byronherbalist.com.au/gut-health/sibo-complete-guide/. Abgerufen am 30.03.2024.
  • Martyniak A, et al.: Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD. In: Biomolecules. 2021 Dec 18;11(12):1903.
  • Matsunami M, et al.: Luminal hydrogen sulfide plays a pronociceptive role in mouse colon. In: Gut. 2009 Jun;58(6):751-761.
  • Maydych V, et al: Impact of chronic and acute academic stress on lymphocyte subsets and monocyte function. Veröffentlicht im November 2019. Abrufbar unter: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0188108. Abgerufen am 02.04.2024.
  • McFarland LV, Karakan T, Karatas A: Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. In: EClinicalMedicine. 2021 Oct 18;41:101154.
  • Melzer J, et al.: Iberis amara L. and Iberogast® – results of a systematic review concerning functional dyspepsia. In: J Herb Pharmacother. 2004;4(4):51-59.
  • Mibiota: Blähbauch und SIBO. Zu wenig Magensäure kann die Ursache sein. Abrufbar unter: https://mibiota.eu/blog/blaehbauch-und-sibo-die-rolle-der-magensaeure/. Abgerufen am 10.05.2023.
  • Michael R, Bettina V, Eckehard L: Functional gastrointestinal disorders in children: Effectivity, safety, and tolerability of the herbal preparation STW-5 (Iberogast®) in general practice. In: Complement Ther Med. 2022 Dec;71:102873.
  • Micklefield GH, et al.: Effects of ginger on gastroduodenal motility. In: Int J Clin Pharmacol Ther. 1999 Jul;37(7):341-346.
  • Mochiki E, et al.: The effect of traditional Japanese medicine (Kampo) on gastrointestinal function. In: Surg Today. 2010 Dec;40(12):1105-1111.
  • Mostafa AA, et al.: Antimicrobial activity of some plant extracts against bacterial strains causing food poisoning diseases. In: Saudi Journal of Biological Sciences. 2018 Feb; 25(2):361-366.
  • Müsken M, et al.: Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing Pseudomonas aeruginosa. In: Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01635-18.
  • Mukherjee P, et al.: Clinical Study of ‘Triphala’ – A Well Known Phytomedicine from India. In: IJPT. 2006(5):51-54.
  • Mullen P: Podcast – SIBO and Gut Health. Abrufbar unter: https://mullenhealth.com.au/mullen-resources/podcast-sibo-and-gut-health/. Abgerufen am 02.04.2024.
  • Nagano T, Itoh H, Takeyama M: Effect of Dai-kenchu-to on levels of 3 brain-gut peptides (motilin, gastrin and somatostatin) in human plasma. In: Biol Pharm Bull. 1999 Oct;22(10):1131-1133.
  • Nascimento GGF, et al.: Antibacterial activity of plant extracts and phytochemicals on antibiotic-resistant bacteria. In: Environmental and Soil Microbiology, Braz. J. Microbiol. 2000 Oct;31(4).
  • National Library of Medicine: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Abrufbar unter: https://www.ncbi.nlm.nih.gov/books/NBK556475/. Abgerufen am 28.03.2020.
  • Neubauer A: Die geheime Kraft der Zähne. Riva 2023.
  • Ng WJ, et al.: Ginger-Enriched Honey Attenuates Antibiotic Resistant Pseudomonas aeruginosa Quorum Sensing Virulence Factors and Biofilm Formation. In: Antibiotics (Basel). 2023 Jun 28;12(7):1123.
  • Nickles MA, et al.: Alternative Treatment Approaches to Small Intestinal Bacterial Overgrowth: A Systematic Review. In: J Altern Complement Med. 2021 Feb;27(2):108-119.
  • Nikkhah Bodagh M, Maleki I, Hekmatdoost A: Ginger in gastrointestinal disorders: A systematic review of clinical trials. In: Food Sci Nutr. 2018 Nov 5;7(1):96-108.
  • Noman ZA, et al.: Evaluation of antibacterial efficacy of garlic (Allium sativum) and ginger (Zingiber officinale) crude extract against multidrug-resistant (MDR) poultry pathogen. In: J Adv Vet Anim Res. 2023 Jun 30;10(2):151-156
  • Ogran A, et al.: The Plant Host Induces Antibiotic Production To Select the Most-Beneficial Colonizers. In: Appl Environ Microbiol. 2019 Jun 17;85(13):e00512-19.
  • Ohashi Y, et al.: Consumption of partially hydrolysed guar gum stimulates Bifidobacteria and butyrate-producing bacteria in the human large intestine. In: Benef Microbes. 2015;6(4):451-5.
  • Ojetti V, et al.: The effect of lactobacillus reuteri (DSM 17938) on methane production in patients affected by functional constipation: a retrospective study. In: Gastroenterology. 2017;152(5):1008.
  • Orfanos-Boeckel H: Nährstoff-Therapie. Der Praxisleitfaden. Trias 2024.
  • Orfanos-Boeckel, H: Nährstoff-Therapie. Trias 2022.
  • Ottilinger B, et al.: STW 5 (Iberogast®)–a safe and effective standard in the treatment of functional gastrointestinal disorders. In: Wien Med Wochenschr. 2013 Feb;163(3-4):65-72.
  • Oude Nijhuis RAB, et al.: The Effect of STW5 (Iberogast®) on Reflux Symptoms in Patients With Concurrent Dyspeptic Symptoms: A Double-blind Randomized Placebo-controlled Crossover Trial. J Neurogastroenterol Motil. 2024 Jan 30;30(1):54-63.
  • Palsson OS, Ballou S: Hypnosis and cognitive behavioral therapies for the management of gastrointestinal disorders. In: Curr Gastroenterol Rep. 2020;22(7):31.
  • Parodi A, et al.: Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. American Journal of Gastroenterology. 2008 May;103(5):1257-1262.
  • Peinado Fabregat MI, et al.: Small Intestinal Bacterial Overgrowth in Children: Clinical Features and Treatment Response. In: JPGN Rep. 2022 Mar 17;3(2):e185.
  • Phan THL, et al.: The Role of Processed Aloe vera Gel in Intestinal Tight Junction: An In Vivo and In Vitro Study. In: Int J Mol Sci. 2021 Jun; 22(12):6515.
  • Pharmazeutische Zeitung: Wald hält gesund. Abrufbar unter: https://www.pharmazeutische-zeitung.de/farbenpraechtiger-seelenschmeichler-136619/seite/2/?cHash=13b5ff285d50dbe5f694ee9c4c7b953c. Abgerufen am 03.03.2024.
  • Phillips SF, et al.: Motility of the ileocolonic junction. In: Gut. 1988;29:390.
  • Piewngam P, et al.: Pathogen elimination by probiotic Bacillus via signalling interference. In: Nature. 2018 Oct;562(7728):532-537.
  • Pilichiewicz AN, et al.: Effects of Iberogast® on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. In: Am J Gastroenterol. 2007 Jun;102(6):1276-83.
  • Pimentel M: A New Ibs Solution: Bacteria-the Missing Link in Treating Irritable Bowel Syndrome. Health Point Press 2006.
  • Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrom: a double-blinde, randomized, placebo-controlled study. In: Am J Gastroenterol. 2003 Feb;98(2):412-419.
  • Pimentel M, Mathur R, Chang C: Gas and the microbiome. In: Curr Gastroenterol Rep. 2013 Dec;15(12):356.
  • Pimentel M, Rezaie A: The Microbiome Connection. Your Guide to IBS, SIBO and Low-fermentation Eating. Agate 2022.
  • Pimentel M, et al.: Clinical Understanding of the Human Gut Microbiome. Springer 2024.
  • Pimentel M, et al.: Antibiotic treatment of constipation-predominant irritable bowel syndrome. In: Dig Dis Sci. 2014 Jun;59(6):1278-1285.
  • Pimentel M, et al.: Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. In: Dig Dis Sci. 2011 Jul;56(7):2067-2072.
  • Pimentel M, et al.: Rifaximin therapy for patients with irritable bowel syndrome without constipation. In: N Engl J Med. 2011 Jan 6;364(1):22-32.
  • Pimentel M, et al.: Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. In: Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435-442.
  • Pimentel M, et al: A 14-day elemental diet is highly effective in normalizing the lactulose breath test. In: Dig Dis Sci. 2004 Jan;49(1):73-77.
  • Plaza-Diaz J, et al.: Mechanisms of Action of Probiotics. In: Adv Nutr. 2020 Jul; 11(4):1054.
  • Ploesser J, Weinstock LB, Thomas E: Low dose naltrexone: side effects and efficacy in gastrointestinal disorders. In: Int J Pharm Compd. 2010 Mar-Apr;14(2):171-173.
  • Posserud I, et al.: Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. In: Gut. 2007;56:802–808.
  • Ponziani FR, Gerardi V, Gasbarrini A: Diagnosis and treatment of small intestinal bacterial overgrowth. In: Expert Rev Gastroenterol Hepatol. 2016;10(2):215-227.
  • Prajapati N, et al.: Postbiotic production: harnessing the power of microbial metabolites for health applications. In: Front Microbiol. 2023 Dec 19;14:1306192.
  • Preuss HG, et al.: Wild garlic has a greater effect than regular garlic on blood pressure and blood chemistries of rats. In: Int Urol Nephrol. 2001;32:525–553.
  • Prizont R: Glycoprotein Degradation in the Blind Loop Syndrome. In: J Clin Invest. 1981 Feb; 67(2):336-344.
  • Pschyrembel. Klinisches Wörterbuch. Thieme, 269. Aufl. 2023.
  • Quigley E, Pot B, Sanders ME: Brain Fogginess‘ and D-Lactic Acidosis: Probiotics Are Not the Cause. In: Clinical and translational gastroenterology. 2018 9(9):187. 
  • Raedsch R, et al.: Wirksamkeit und Unbedenklichkeit des Phytopharmakons STW 5 versus Metoclopramid bei funktioneller Dyspepsie unter Praxisbedingungen – eine retroelektive Kohortenstudie. In: Z Gastroenterol. 2007; 45(10):1041-1048.
  • Ranjbar-Omid M, et al.: Allicin from garlic inhibits the biofilm formation and urease activity of Proteus mirabilis in vitro. In: FEMS Microbiology Letters. 2015 May;362(9):fnv049.
  • Rao SSC, Bhagatwala J: Small intestinal bacterial overgrowth: clinical features and therapeutic management. In: Clin Transl Gastroenterol. 2019;10(10):e00078.
  • Rao SSC, et al.: Brain fogginess, gas and bloating: a link between SIBO, probiotics and metabolic acidosis. In: Clin Transl Gastroenterol. 2018 Jun 19;9(6):162.
  • Reizdarm SOS: https://www.reizdarm-sos.de/
  • Ren X, et al.: Chinese herbal medicine for the treatment of small intestinal bacterial overgrowth (SIBO): A protocol for systematic review and meta-analysis. In: Medicine (Baltimore). 2020 Dec 18;99(51):e23737.
  • Rezaie A, Pimentel M, Rao SS: How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. In: Curr Gastroenterol Rep. 2016;18(2):8.
  • Rezaie A, et al.: Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. In: Am J Gastroenterol. 2017;112(5):775-784.
  • Richard N, et al.: The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth. In: United European Gastroenterol J. 2021 Jul;9(6):645-654.
  • Riepe SP, Goldstein J, Alpers DH: Effect of Secreted Bacteroides Proteases on Human Intestinal Brush Border Hydrolases. In: J Clin Invest. 1980;66(2):314-322.
  • Riordan SM, et al.: Small intestinal bacterial overgrowth in the symptomatic elderly. In: Am J Gastroenterol. 1997 Jan;92(1):47-51.
  • Riordan SM, et al.: Luminal bacteria and small-intestinal permeability. In: Scand J Gastroenterol. 1997 Jun;32(6):556-563.
  • Ritz NL, et al.: Sulfate-reducing bacteria impairs working memory in mice. In: Physiol Behav. 2016 Apr 1:157:281-287.
  • Robinson-Papp J, et al.: The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies. In: J Neurovirol. 2019 Aug;25(4):551-559.
  • Rodriguzez DA, et al.: Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. In: Front Pediatr. 2019 Sep 4:7:363.
  • Rodriguez Ayala F, Bartolini M, Grau R: The Stress-Responsive Alternative Sigma Factor SigB of Bacillus subtilis and Its Relatives: An Old Friend With New Functions. In: Front Microbiol. 2020 Sep 15;11:1761.
  • Roediger WE, Moore J, Babidge W: Colonic sulfide in pathogenesis and treatment of ulcerative colitis. In: Dig Dis Sci. 1997 Aug;42(8):1571-1579.
  • Rösch W, Vinson B, Sassin I: A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. In: Z Gastroenterol. 2002 Jun;40(6):401-408.
  • Roland BC, et al.: Low ileocecal valve pressure is significantly associated with small intestinal bacterial overgrowth (SIBO). In: Dig Dis Sci. 2014 Jun;59(6):1269-1277.
  • Rosenblatt J, et al.: Caprylic and Polygalacturonic Acid Combinations for Eradication of Microbial Organisms Embedded in Biofilm. In: Front Microbiol. 2017; 8:1999.
  • Roslund K, et al.: Volatile composition of the morning breath. In: J Breath Res. 2022 Sep 19;16(4).
  • Rostami A, et al.: The role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis. In: Parasitol Res. 2017 Sep;116(9):2361–2371.
  • Roy M, et al.: STW5 (Iberogast®) for constipation in Parkinson’s disease. In: Rev Neurol (Paris). 2021 Mar;177(3):296-301.
  • Rubio-Tapia A, et al.: Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. In: J Clin Gastroenterol. 2009;43:157-161.
  • Sachdeva S, et al.: Brain Fogginess and SIBO: A Link or Just a Mirage? In: Clin Transl Gastroenterol. 2018 Sep 20;9(9):184.
  • Saller R, et al.: Iberogast®: a modern phytotherapeutic combined herbal drug for the treatment of functional disorders of the gastrointestinal tract (dyspepsia, irritable bowel syndrome)–from phytomedicine to „evidence based phytotherapy.“ A systematic review. In: Forsch Komplementarmed Klass Naturheilkd. 2002 Dec;9 Suppl 1:1-20.
  • Saltzmann JR, Russell RM: Nutritional consequences of intestinal bacterial overgrowth. In: Compr Ther. 1994;20(9):523-530.
  • Saltzman JR, et al.: Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. In: Gastroenterology. 1994 Mar;106(3):615-623.
  • Sandberg-Lewis S: Functional Gastroenterology. Assessing and Addressing the Causes of Functional Gastrointestinal Disorders. NCNM Press, 2. Auflage 2017.
  • Sarna S: Healing SIBO. Fix the Real Cause of IBS, Bloating, and Weight Issues in 21 Days. Avery 2021.
  • Schemann M, et al.: Region-specific effects of STW 5 (Iberogast®) and its components in gastric fundus, corpus and antrum. In: Phytomedicine. 2006;13 Suppl 5:90-99.
  • Schempp H, et al.: Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast®) and its components. In: Phytomedicine. 2006;13 Suppl 5:36-44.
  • Schmidbauer C, Hofstätter G (Hrsg.): Mikronährstoffcoach. Das große BIOGENA-Kompendium der Nährstoffe. Verlagshaus der Ärzte, 4. Auflage 2020.
  • Shah ED, et al.: Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. In: Aliment Pharmacol Ther. 2013 Oct;38(8):925-934.
  • Shah A, et al.: Links between celiac disease and small intestinal bacterial overgrowth: A systematic review and meta-analysis. In: J Gastroenterol Hepatol. 2022 Oct;37(10):1844-1852.
  • Shah ED, et al.: Estimating the Contribution of Acute Gastroenteritis to the Overall Prevalence of Irritable Bowel Syndrome. In: J Neurogastroenterol Motil. 2012 Apr; 18(2):200-204.
  • Sharkey KA, Mawe GM: The enteric nervous system. In: Physiol Rev. 2023 Apr 1;103(2):1487-1564.
  • Sheptulin AA, Belousova IB: MODERN PROKINETICS AND THEIR ROLE IN THE TREATMENT OF GASTROENTEROLOGICAL PATHOLOGY. In: Klin Med (Mosk). 2016;94(3):178-182.
  • Shindo K, et al.: Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. In: Hepatogastroenterology. 1998 Sep-Oct;45(23):1643-1650.
  • Sibotesting: What Causes SIBO? – Bile and Enzymes. Veröffentlicht am 23. November 2015. Abrufbar unter: https://sibotesting.com/what-causes-sibo-bile-and-enzymes/. Abgerufen am 02.04.2024.
  • Siddique DA, et al.: Clinical Presentation of Small Intestinal Bacterial Overgrowth from Aerodigestive Tract Bacteria Versus Colonic-Type Bacteria: A Comparison Study. In: Dig Dis Sci. 2023 Aug;68(8):3390-3399.
  • Siebecker A: SIBO Pro Course. Education for Professionals. Stand 2023. Abrufbar unter: http://www.siboinfo.com. Abgerufen 13.10.2023.
  • Siebecker A: SIBO-Specific Diet: Food Guide. Abrufbar unter: https://www.siboinfo.com/uploads/5/4/8/4/5484269/sibo_specific_diet_food_guide_sept_2014.pdf&ved=2ahUKEwimoJ-TuJWFAxVuywIHHT7_CmYQFnoECBIQAQ&usg=AOvVaw3PKxIWp6toM4mFL8bOoJLH. Abgerufen am 27.03.2024.
  • Sieczkowska A, et al.: Long-term proton pump inhibitor therapy leads to small bowel bacterial overgrowth as determined by breath hydrogen and methane excretion. In: J Breath Res. 2018 Mar 12;12(3):036006.
  • Simmen U, et al.: Binding of STW 5 (Iberogast®) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. In: Phytomedicine. 2006:13 Suppl 5:51-55.
  • Singer-Englar T, et al.: 182 – Competitive Hydrogen Gas Utilization by Methane- and Hydrogen Sulfide-Producing Microorganisms and Associated Symptoms: Results of a Novel 4-Gas Breath Test Machine. In: Gastroenterology. 154(6):S-47.
  • Skrzydło-Radomańska B, et al: The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome-A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. In: J Clin Med. 2023 Jul 22;12(14):4838.
  • Skrzydlo-Radomańska B, Cukrowska B: How to Recognize and Treat Small Intestinal Bacterial Overgrowth? In: J Clin Med. 2022 Oct 12;11(20):6017.
  • Sommer A: Angststörung und Reizdarmsyndrom – was hilft? Abrufbar unter: https://cara.care/de/erkrankungen/reizdarm/angststoerung-und-reizdarmsyndrom-was-hilft/. Abgerufen am 03.03.2024.
  • Song YJ, et al.: Anti-Biofilm Activity of Grapefruit Seed Extract against Staphylococcus aureus and Escherichia coli. In: J Microbiol Biotechnol. 2019 Aug 28;29(8):1177-1183.
  • Souza C, Rocha R, Pinchemel Cotrim H: Diet and intestinal bacterial overgrowth: Is there evidence?. In: World J Clin Cases. 2022 May 26;10(15):4713-4716.
  • Sroka N, et al.: Show Me What You Have Inside-The Complex Interplay between SIBO and Multiple Medical Conditions-A Systematic Review. In: Nutrients. 2022 Dec 24;15(1):90.
  • Statista: Wie oft haben Sie in den letzten 12 Monaten Magen- bzw. Darmbeschwerden gehabt?. Veröffentlicht am 06.11.2019. Abrufbar unter: https://de.statista.com/statistik/daten/studie/668053/umfrage/umfrage-zur-haeufigkeit-von-magen-bzw-darmbeschwerden-in-deutschland/ Abgerufen am 10.1.2024.
  • Storr M, Scheidhauer K: Chologene Diarrhoe: Der Weg in die Beschwerdefreiheit. 04.07.2022. CME-Kurs. Abrufbar unter: https://www.cme-kurs.de/kurse/chologene-diarrhoe-der-weg-in-die-beschwerdefreiheit/. Abgerufen im Juli 2022.
  • Su T, et al.: Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. In: J Gastroenterol. 2018 Jan;53(1):27-36.
  • Suarez FL, et al.: Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. In: Gastroenterology. 1998 May;114(5):923-929.
  • Subapriya R, Nagini S: Medicinal properties of neem leaves: a review. In: Curr Med Chem Anticancer Agents. 2005 Mar;5(2):149-146.
  • Suskind DL, et al. Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease. In: Dig Dis Sci. 2016 Nov;61(11):3255-3260.
  • Takakura W, et al.: Symptomatic Response to Antibiotics in Patients With Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-analysis. In: J Neurogastroenterol Motil. 2024 Jan 30;30(1):7-16.
  • Takakura W, et al.: Sa1215 USING A NOVEL 4-GAS BREATH TEST DEVICE, MULTIVARIABLE ANALYSIS REVEALS AN ASSOCIATION BETWEEN EXCESSIVE HYDROGEN SULFIDE ON BREATH TESTING AND HEARTBURN. In: Gastroenterology. 2020 May;158(6):S-315.
  • Takakura W: Antibiotics for Dyspepsia: Hp, SIBO, IMO, or Something Else? In: Dig Dis Sci. 2024 Feb 15. Abrufbar unter: https://doi.org/10.1007/s10620-024-08281-4. Abgerufen am 18.05.2024.
  • Tarasiuk A, Mosínska P, Fichna J: Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders. In: Chinese Medicine. 2018 Jul;13(39). Abrufbar unter: https://doi.org/10.1186/s13020-018-0197-6. Abgerufen am 18.05.2024.
  • Terada Y, Kawabata A: H2S and Pain: A Novel Aspect for Processing of Somatic, Visceral and Neuropathic Pain Signals. In: Handb Exp Pharmacol. 2015;230:217-230.
  • Tillman LA, et al.: Review article: safety of bismuth in the treatment of gastrointestinal diseases. In: Aliment Pharmacol Ther. 1996 Aug;10(4):459-467.
  • Tominaga K, Arakawa T: Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application. In: J Gastroenterol. 2013 Apr;48(4):452-462.
  • Uchikawa T, et al.: Chlorella suppresses methylmercury transfer to the fetus in pregnant mice. In: The Journal of Toxicological Sciences. 2011;36(5):675-680.
  • Uchikawa T, et al.: The enhanced elimination of tissue methylmercury in Parachlorella beijerinckii-fed mice. In: The Journal of Toxicological Sciences. 2011; 36(1):121-126.
  • Ursinus L: Blutwerte ganzheitlich interpretieren. Schirner Verlag 2024.
  • Ursinus L: Der Darm, die Wurzel der Gesundheit. Schirner Verlag 2022.
  • Ursinus L: Mein Blut sagt mir… Labor ganzheitlich. Schirner Verlag 2015.
  • van Tilburg MA, et al.: Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. In: Complement Ther Med. 2014 Feb;22(1):17-20.
  • Vanderhoof JA, et al.: Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. In: J Pediatr Gastroenterol Nutr. 1998 Aug;27(2):155-160.
  • Vantrappen G, et al.: The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. In: J Clin Invest. 1977;59:1158.
  • Vasant DH, Whorwell PJ: Gut-focused hypnotherapy for functional gastrointestinal disorders: evidence-base, practical aspects, and the Manchester Protocol. In: Neurogastroenterol Motil. 2019;31(8):e13573.
  • Videlock EJ, et al.: Childhood trauma is associated with hypothalamic-pituitary-adrenal axis responsiveness in irritable bowel syndrome. In: Gastroenterology. 2009 Dec;137(6):1954-62.
  • Villanueva-Millan MJ, et al.: Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes. In: Am J Gastroenterol. 2022 Dec 1;117(12):2055-2066.
  • Vinderola G, et al.: Frequently asked questions about the ISAPP postbiotic definition. In: Front Microbiol. 2024 Jan 10;14:1324565.
  • Vojdani A, Vojdani E: Reaction of antibodies to Campylobacter jejuni and cytolethal distending toxin B with tissues and food antigens. In: World J Gastroenterol. 2019 Mar 7;25(9):1050–1066.
  • Wang J, Zhang L, Hou X: Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. In: Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1385-1399.
  • Wang L, et al.: Hydrogen breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in autism. In: Eur Child Adolesc Psychiatry. 2018 Feb;27(2):233-240.
  • Wegener T, Wagner H: The active components and the pharmacological multi-target principle of STW 5 (Iberogast®). Phytomedicine. 2006;13 Suppl 5:20-35.
  • Weinstock LB, Klutke CG, Lin HC: Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. In: Dig Dis Sci. 2008 May;53(5):1246-1251.
  • Wielgosz-Grochowska JP, Domanski N, Drywień ME: Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review. In: Nutrients. 2022 Aug 17;14(16):3382.
  • Wira Septama A, et al.: Essential Oil of Zingiber cassumunar Roxb. and Zingiber officinale Rosc.: A Comparative Study on Chemical Constituents, Antibacterial Activity, Biofilm Formation, and Inhibition of Pseudomonas aeruginosa Quorum Sensing System. In: Chem Biodivers. 2023 Jun;20(6):e202201205.
  • Wu KuL, et al.: Effects of ginger on gastric emptying and motility in healthy humans. In: Eur J Gastroenterol Hepatol. 2008 May;20(5):436-440.
  • Wu X, Santos RR, Fink-Gremmels J: Analyzing the antibacterial effects of food ingredients: model experiments with allicin and garlic extracts on biofilm formation and viability of Staphylococcus epidermidis. In: Food Sci Nutr. 2015 Mar;3(2):158-168.
  • Yago MR, et al.: Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. In: Mol Pharm. 2013 Nov 4;10(11):4032-7.
  • Yao CK, Tuck CJ. The clinical value of breath hydrogen testing. J Gastroenterol Hepatol. 2017;32(suppl 1):20-22.
  • Yokoyama K, et al.: Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. In: PLoS One. 2022 Feb 25;17(2):e0264459.
  • Yuyama KT, et al.: Unsaturated Fatty Acids Control Biofilm Formation of Staphylococcus aureus and Other Gram-Positive Bacteria. In: Antibiotics (Basel). 2020 Nov; 9(11):788.
  • Zafar H, Jimenez B, Schneider A: Small intestinal bacterial overgrowth: current update. In: Curr Opin Gastroenterol. 2023 Nov 1;39(6):522-528.
  • Zafar H, et al.: Small Intestinal Bacterial Overgrowth: A Critical Review of an Underrecognized but Disrupting Entity. In: Crit Rev Oncog. 2020;25(4):365-379.
  • Zaidel O, Lin HC: Uninvited guests: The impact of small intestinal bacterial overgrowth on nutritional status. In: Practical Gastroenterology. 27(7):27-30+33.
  • Zappe A, Klinghardt D: ImmunSymbiose: Immuntoleranz durch Kommunikation und Frieden mit Mikroben. SophiaMed UG 2017.
  • Zhang H, Li S, Cheng Y: Antibiofilm Activity of Allicin and Quercetin in Treating Biofilm-Associated Orthopaedics Infection. In: Appl Biochem Biotechnol. 2022 Feb 10. doi: 10.1007/s12010-022-03845-4. Epub ahead of print.
  • Zhong C, et al.: Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. In: J Clin Gastroenterol. 2017 Apr;51(4):300-311.
  • Zhu D, et al.: Influence of Helicobacter pylori infection and its eradication treatment on small intestinal bacterial overgrowth. In: Zhonghua Yi Xue Za Zhi. 2022 Nov 15;102(42):3382-3387
  • Wilhelmi M, et al.: SIBO „small intestinal bacterial overgrowth“. Veröffentlicht am 28.02.2018. Abrufbar unter: https://medicalforum.ch/de/detail/doi/smf.2018.03208. Abgerufen am 04.04.2024.